Page 14 - Neil Kumar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BridgeBio Pharma Inc (NASDAQ:BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 st...

- In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03...

Renaissance Technologies LLC raised its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 230.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,366,746 shares of the company’s stock after acquiring an additional 953,500 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of BridgeBio […]

23.02.2023 - –Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 ...

Cowen assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Rating) in a research report report published on Monday morning, The Fly reports. The brokerage issued an outperform rating on the stock. BBIO has been the subject of a number of other research reports. JPMorgan Chase & Co. reduced their price objective on BridgeBio […]